Payment overview · 2025
General Payments
$765.63
31 reported records · 15 companies
Healthcare provider profile · identity verified
Christi Ann Wallace, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROANOKE, IN · NPI 1346535358
Verified facts
What the public records show
CMS Open Payments records show Christi Ann Wallace, MD received $765.63 in general payments during 2025 across 31 reported records.
Corcept Therapeutics accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta, Trintellix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $174.05 | 22.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.39 | 20.0% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $109.12 | 14.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.45 | 6.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.15 | 6.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.36 | 4.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.82 | 4.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.33 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.49 | 2.8% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.57 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.25 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.27 | 2.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.19 | 2.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.66 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $765.63 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $174.05 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.48 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $109.12 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.45 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.45 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
138 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 66 |
| Lisinopril | Lisinopril | 226 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 56 |
| Losartan Potassium | Losartan Potassium | 154 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 47 |
| Omeprazole | Omeprazole | 140 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 47 |
| Mounjaro | Tirzepatide | 138 | 23 |
| Metformin Hcl | Metformin Hcl | 107 | 33 |
| Carvedilol | Carvedilol | 103 | 32 |
| Furosemide | Furosemide | 102 | 32 |
| Trazodone Hcl | Trazodone Hcl | 96 | 29 |
| Gabapentin | Gabapentin | 89 | 30 |
| Simvastatin | Simvastatin | 87 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 28 |
| Ozempic | Semaglutide | 82 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 36 |
| Farxiga | Dapagliflozin Propanediol | 67 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 17 |
| Meloxicam | Meloxicam | 55 | 21 |
| Bupropion Xl | Bupropion Hcl | 54 | 20 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 16 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Prednisone | Prednisone | 44 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 17 |
| Allopurinol | Allopurinol | 42 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Spironolactone | Spironolactone | 40 | 14 |
| Famotidine | Famotidine | 39 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 25 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 15 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | 12 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $765.63 · 31 records | Corcept Therapeutics | AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, ELIQUIS, JARDIANCE, JATENZO, Jornay PM, Korlym, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, STRENSIQ, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error